[go: up one dir, main page]

WO2009020093A1 - デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム - Google Patents

デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム Download PDF

Info

Publication number
WO2009020093A1
WO2009020093A1 PCT/JP2008/063958 JP2008063958W WO2009020093A1 WO 2009020093 A1 WO2009020093 A1 WO 2009020093A1 JP 2008063958 W JP2008063958 W JP 2008063958W WO 2009020093 A1 WO2009020093 A1 WO 2009020093A1
Authority
WO
WIPO (PCT)
Prior art keywords
immunoliposome
cell expressing
death domain
containing receptor
inducing apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/063958
Other languages
English (en)
French (fr)
Inventor
Koji Morita
Takako Niwa
Kimihisa Ichikawa
Hiroko Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Priority to JP2009526446A priority Critical patent/JPWO2009020093A1/ja
Priority to US12/672,870 priority patent/US20100209490A1/en
Priority to CA2695991A priority patent/CA2695991A1/en
Priority to CN200880110766A priority patent/CN101820913A/zh
Priority to EP08792162A priority patent/EP2177230A4/en
Publication of WO2009020093A1 publication Critical patent/WO2009020093A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

　本発明は、癌、自己免疫疾患または炎症性疾患に対して治療効果を有するイムノリポソーム製剤に関する。すなわち、本発明は、デスドメイン含有受容体発現細胞にアポトーシスを誘導可能な抗体を構成成分とするイムノリポソームに関する。
PCT/JP2008/063958 2007-08-09 2008-08-04 デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム Ceased WO2009020093A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2009526446A JPWO2009020093A1 (ja) 2007-08-09 2008-08-04 デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム
US12/672,870 US20100209490A1 (en) 2007-08-09 2008-08-04 Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor
CA2695991A CA2695991A1 (en) 2007-08-09 2008-08-04 Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor
CN200880110766A CN101820913A (zh) 2007-08-09 2008-08-04 在表达含死亡结构域的受体的细胞中诱导细胞凋亡的免疫脂质体
EP08792162A EP2177230A4 (en) 2007-08-09 2008-08-04 IMMUNOLIPOSOM AS INDUCTOR OF APOPTOSIS INTO DEATH DOMAIN-CONTAINING RECEPTOR EXPRESSING CELL

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-208664 2007-08-09
JP2007208664 2007-08-09

Publications (1)

Publication Number Publication Date
WO2009020093A1 true WO2009020093A1 (ja) 2009-02-12

Family

ID=40341326

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2008/063959 Ceased WO2009020094A1 (ja) 2007-08-09 2008-08-04 疎水性分子で修飾した抗体
PCT/JP2008/063958 Ceased WO2009020093A1 (ja) 2007-08-09 2008-08-04 デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/063959 Ceased WO2009020094A1 (ja) 2007-08-09 2008-08-04 疎水性分子で修飾した抗体

Country Status (8)

Country Link
US (2) US20110269942A1 (ja)
EP (2) EP2177230A4 (ja)
JP (2) JPWO2009020094A1 (ja)
KR (1) KR20100046185A (ja)
CN (1) CN101820913A (ja)
CA (1) CA2695991A1 (ja)
TW (2) TW200916477A (ja)
WO (2) WO2009020094A1 (ja)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209490A1 (en) * 2007-08-09 2010-08-19 Daiichi Sankyo Company, Limited Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor
JP2011032264A (ja) * 2009-07-06 2011-02-17 Canon Inc 標識タンパク質及びその取得方法
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ
JPWO2012093733A1 (ja) * 2011-01-07 2014-06-09 セイコーエプソン株式会社 抗シグナルペプチド抗体の製造方法
EP2480230A4 (en) * 2009-09-24 2015-06-10 Seattle Genetics Inc DR5 Ligand-HEILMITTELKONJUGATE
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
US9370182B2 (en) 2012-05-28 2016-06-21 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
US9480727B2 (en) 2012-10-18 2016-11-01 Toagosei Co. Ltd. Synthetic peptide for inhibiting expression of type 2 TNF receptor and use thereof
CN107753434A (zh) * 2017-12-06 2018-03-06 西南交通大学 一种包载亲疏水性不同药物的载药脂质体及其制备方法与应用
JP2021514945A (ja) * 2018-02-26 2021-06-17 アイジーエム バイオサイエンシズ インコーポレイテッド がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用
WO2023204290A1 (ja) * 2022-04-21 2023-10-26 愛知県 多重特異性ナノ粒子

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2848173C (en) * 2011-05-10 2019-07-02 The Penn State Research Foundation Ceramide anionic liposome compositions
DK2706988T3 (da) * 2011-05-12 2020-01-20 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Liposomer omfattende polymer konjugerede lipider og relateret brug
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
US9610250B2 (en) * 2012-04-12 2017-04-04 Yale University Nanolipogel vehicles for controlled delivery of different pharmaceutical agents
TWI585101B (zh) * 2012-11-16 2017-06-01 財團法人農業科技研究院 製備抗體Ｆ（ａｂ’）２片段之方法
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
CA2929277C (en) 2013-11-01 2018-01-16 Yale University Delivery vehicles comprising il-2 and losartan
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
CA2942235A1 (en) * 2014-03-12 2015-09-17 Glaxosmithkline Biologicals S.A. Immunogenic liposomal formulation
US20170173005A1 (en) 2014-03-27 2017-06-22 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
EP4464332A1 (en) * 2014-03-31 2024-11-20 Hanmi Pharm. Co., Ltd. Composition for improving the solubility of a protein or peptide by using immunoglobulin fc fragment linkage
CN107847444A (zh) * 2015-05-26 2018-03-27 通用医疗公司 脂质体纳米构建体及其制备和使用方法
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
CN109195620B (zh) 2016-04-07 2022-06-28 约翰霍普金斯大学 用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
CA3051481A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
WO2018170398A1 (en) * 2017-03-16 2018-09-20 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
EP3665480A4 (en) * 2017-08-09 2021-05-12 The Regents Of The University Of Michigan STRUCTURES FOR IMITATING APOPTOSIS
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞の使用方法
CN111936518A (zh) 2018-02-06 2020-11-13 西雅图儿童医院（Dba西雅图儿童研究所） 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
MX2021011242A (es) * 2019-03-21 2022-01-19 Codiak Biosciences Inc Conjugados de vesícula extracelular y usos de estos.
IT202000004846A1 (it) * 2020-03-06 2021-09-06 Univ Degli Studi G Dannunzio Chieti Pescara Pro-drug innovativo micellare su backbone polimerico del Killer TNF-apoptosis induced ligand.
IT202000013042A1 (it) * 2020-06-01 2021-12-01 Univ Degli Studi G Dannunzio Chieti Pescara Sistema liposomiale con killer tnf-apoptosis induced ligand (killertrail), pro-apoptotico-direzionante.
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
WO2022040435A1 (en) * 2020-08-19 2022-02-24 The Board Of Regents Of The University Of Texas System Nanodrugs for targeted drug delivery and use thereof
WO2022136939A1 (en) * 2020-12-21 2022-06-30 Samarth Zarad A method for preparation of a drug encapsulated liposome in an organic solvent emulsion
CN114150007B (zh) * 2021-12-14 2023-07-21 扬州大学 一种适用于家兔乳腺特异性表达去氨普酶的编码基因及其应用
CN115181720B (zh) * 2022-07-27 2023-06-30 天津鸿宇泰生物科技有限公司 一种无血清培养基及其应用、一种cho细胞表达重组抗体的构建方法
CN116908335B (zh) * 2023-08-25 2025-09-26 遂成药业股份有限公司 一种高效液相色谱法检测卤代植物醇含量的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09110722A (ja) * 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
JP2002537318A (ja) * 1999-02-22 2002-11-05 ジョージタウン・ユニバーシティ 全身性遺伝子送達のための抗体標的化フラグメントイムノリポソーム
JP2003520603A (ja) * 2000-01-28 2003-07-08 メディツィニッシェ・ホッホシューレ・ハノーヴァー 未分化および髄様甲状腺癌、非甲状腺癌、およびそれらの転移癌の遺伝子治療に媒介される放射性核種内用療法のためのベクター構築物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6972323B1 (en) * 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
EP1537858A1 (en) * 2003-12-04 2005-06-08 Vectron Therapeutics AG Drug delivery vehicles and uses thereof
JPWO2005056605A1 (ja) * 2003-12-12 2007-12-06 中外製薬株式会社 ３量体以上の受容体を認識する改変抗体
BRPI0515615A (pt) * 2004-09-08 2008-07-29 Genentech Inc métodos para tratar células cancerosas e doença imune relacionada
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
EP1871424A2 (en) * 2005-04-22 2008-01-02 Alza Corporation Immunoliposome composition for targeting to a her2 cell receptor
US8361462B2 (en) * 2005-09-01 2013-01-29 National Research Council Of Canada Anti-apoptotic protein antibodies
JPWO2009020094A1 (ja) * 2007-08-09 2010-11-04 第一三共株式会社 疎水性分子で修飾した抗体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09110722A (ja) * 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
JP2002537318A (ja) * 1999-02-22 2002-11-05 ジョージタウン・ユニバーシティ 全身性遺伝子送達のための抗体標的化フラグメントイムノリポソーム
JP2003520603A (ja) * 2000-01-28 2003-07-08 メディツィニッシェ・ホッホシューレ・ハノーヴァー 未分化および髄様甲状腺癌、非甲状腺癌、およびそれらの転移癌の遺伝子治療に媒介される放射性核種内用療法のためのベクター構築物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GABRIELLA PAGNAN: "GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide", INT. J. CANCER, vol. 81, 1999, pages 268 - 274, XP001059058 *
MILLSTEIN ET AL., NATURE, vol. 305, 1983, pages 537 - 539
NATURE BIOTECHNOLOGY, vol. 23, 2005, pages 1126 - 1136
PLUCKTHUN: "The Pharmacology of Monoclonal Antibodies", vol. 113, 1994, SPRINGER VERLAG, pages: 269 - 315
SAJID HUSSAIN: "Induction of Tumor Cell Apoptosis and Chemosensitization by Antisense Strategies", MOL. CANCER THER., vol. 5, no. 12, 2006, pages 3170 - 3180 *
See also references of EP2177230A4

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110269942A1 (en) * 2007-08-09 2011-11-03 Daiichi Sankyo Company, Limited Antibodies modified with hydrophobic molecule
US20100209490A1 (en) * 2007-08-09 2010-08-19 Daiichi Sankyo Company, Limited Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor
JP2011032264A (ja) * 2009-07-06 2011-02-17 Canon Inc 標識タンパク質及びその取得方法
US8993715B2 (en) 2009-07-06 2015-03-31 Canon Kabushiki Kaisha Labeled protein and method for obtaining the same
EP2480230A4 (en) * 2009-09-24 2015-06-10 Seattle Genetics Inc DR5 Ligand-HEILMITTELKONJUGATE
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
US9309307B2 (en) 2011-01-07 2016-04-12 Seiko Epson Corporation Antibody against amyloid precursor protein signal peptide
JPWO2012093733A1 (ja) * 2011-01-07 2014-06-09 セイコーエプソン株式会社 抗シグナルペプチド抗体の製造方法
US9370182B2 (en) 2012-05-28 2016-06-21 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ
US9480727B2 (en) 2012-10-18 2016-11-01 Toagosei Co. Ltd. Synthetic peptide for inhibiting expression of type 2 TNF receptor and use thereof
CN107753434A (zh) * 2017-12-06 2018-03-06 西南交通大学 一种包载亲疏水性不同药物的载药脂质体及其制备方法与应用
JP2021514945A (ja) * 2018-02-26 2021-06-17 アイジーエム バイオサイエンシズ インコーポレイテッド がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用
JP7358365B2 (ja) 2018-02-26 2023-10-10 アイジーエム バイオサイエンシズ インコーポレイテッド がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用
WO2023204290A1 (ja) * 2022-04-21 2023-10-26 愛知県 多重特異性ナノ粒子

Also Published As

Publication number Publication date
EP2184355A1 (en) 2010-05-12
CA2695991A1 (en) 2009-02-12
TW200914064A (en) 2009-04-01
US20110269942A1 (en) 2011-11-03
JPWO2009020093A1 (ja) 2010-11-04
JPWO2009020094A1 (ja) 2010-11-04
EP2177230A4 (en) 2011-04-27
EP2184355A4 (en) 2011-04-27
KR20100046185A (ko) 2010-05-06
US20100209490A1 (en) 2010-08-19
CN101820913A (zh) 2010-09-01
WO2009020094A1 (ja) 2009-02-12
EP2177230A1 (en) 2010-04-21
TW200916477A (en) 2009-04-16

Similar Documents

Publication Publication Date Title
WO2009020093A1 (ja) デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム
CY2021027I1 (el) Σκευασματα αντισωματων anti-cd20
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
BRPI0812285A2 (pt) Aperfeiçoamentos para ressucitadores eletricamente operáveis.
GB2447796C (en) Iodonitrobenzamide formulations for cancer and viral diseases.
EP2379594B8 (en) Human cgrp receptor binding antibodies
IS8842A (is) Kjarnviðtaka bindimiðlar.
IL202648A0 (en) Antibody formulations
AU2008225994B2 (en) Monoclonal human tumor-specific antibody
BRPI0715544A2 (pt) Anticorpos que modificam doença cancerosas.
PL1960432T3 (pl) Przeciwciało anty-ICAM indukujące apoptozę
ZA200905062B (en) Cancerous disease modifying antibodies
NL2001260A1 (nl) Tweeband-antenne.
ZA200905064B (en) Cancerous disease modifying antibodies
IL199666A0 (en) Cancerous disease modifying antibodies
GB0707514D0 (en) Saftey line
EP2167635A4 (en) ANTIBODY FORMULATIONS
BRPI0816181A2 (pt) Anticorpos modificadores de doença cancerígena.
ZA200907354B (en) Cancerous disease modifying antibodies
DE602007003092D1 (de) Ringordnermechanik
ZA200704491B (en) Lever-Arch Type File Mechanism
HK1137512A (en) Disease markers
AU3849P (en) Silver Grace Lomandra confertifolia subsp. Rubignosa
HK1142911A (en) Il-18 receptor antigen binding proteins
ITNA20060003U1 (it) Elicottero bimotore biposto.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880110766.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08792162

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009526446

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107002922

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2695991

Country of ref document: CA

Ref document number: 2008792162

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12672870

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0815106

Country of ref document: BR

Free format text: COMO, NO REFERIDO PEDIDO, FOI APRESENTADA LISTAGEM DE SEQUENCIA COM DATA POSTERIOR A RESOLUCAO 228/09, SOLICITA-SE QUE SEJA APRESENTADA A LISTAGEM DE SEQUENCIA EM FORMATO DIGITAL, EM DUAS VIAS CDS/DVDS OU EM PETICIONAMENTO ELETRONICO, COM A RESPECTIVA DECLARACAO E CODIGO ALFANUMERICO, DE ACORDO COM A RESOLUCAO 81/2013.

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0815106

Country of ref document: BR

Free format text: PEDIDO RETIRADO EM RELACAO AO BRASIL POR NAO ATENDER AS DETERMINACOES REFERENTES A ENTRADA DO PEDIDO NA FASE NACIONAL E POR NAO CUMPRIMENTO DA EXIGENCIA FORMULADA NA RPI NO 2376 DE 19/07/2016